CLINICAL TRIALS PROFILE FOR MIRABEGRON
✉ Email this page to a colleague
All Clinical Trials for mirabegron
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00410514 ↗ | A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) | Completed | Astellas Pharma Inc | Phase 2 | 2006-12-01 | This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo. |
| NCT00662909 ↗ | A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2008-03-28 | The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder |
| NCT00688688 ↗ | Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2008-04-25 | The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator. |
| NCT00689104 ↗ | Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | Completed | Astellas Pharma Inc | Phase 3 | 2008-04-28 | The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder. |
| NCT00750620 ↗ | A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment | Completed | Astellas Pharma Inc | Phase 1 | 2008-09-01 | The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment. |
| NCT00776516 ↗ | Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers | Completed | Astellas Pharma Inc | Phase 1 | 2008-10-01 | The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer. |
| NCT00840645 ↗ | A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients | Completed | Astellas Pharma Inc | Phase 3 | 2008-12-01 | The study is intended to test the safety, tolerability, and efficacy of long-term treatment with YM178 in patients with overactive bladder symptoms. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for mirabegron
Condition Name
Clinical Trial Locations for mirabegron
Trials by Country
Clinical Trial Progress for mirabegron
Clinical Trial Phase
Clinical Trial Sponsors for mirabegron
Sponsor Name
